EVAX (Evaxion Biotech AS) Days Payable : 0.00 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS Days Payable?

Evaxion Biotech AS's average Accounts Payable for the three months ended in Sep. 2024 was $2.56 Mil. Evaxion Biotech AS's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Evaxion Biotech AS's Days Payable or its related term are showing as below:

EVAX's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 122.79
* Ranked among companies with meaningful Days Payable only.

Evaxion Biotech AS's Days Payable stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00). stayed the same

Evaxion Biotech AS Days Payable Historical Data

The historical data trend for Evaxion Biotech AS's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS Days Payable Chart

Evaxion Biotech AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Evaxion Biotech AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Evaxion Biotech AS's Days Payable

For the Biotechnology subindustry, Evaxion Biotech AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evaxion Biotech AS's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion Biotech AS's Days Payable distribution charts can be found below:

* The bar in red indicates where Evaxion Biotech AS's Days Payable falls into.

Save Embed

;

Save Embed

;

Evaxion Biotech AS Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Evaxion Biotech AS's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (2.085	+	2.689)	/	2 )	/	0	*	365
=	2.387					/	0	*	365
=	N/A

Evaxion Biotech AS's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (2.558	+	0)	/	1 )	/	0	*	365 / 4
=	2.558					/	0	*	365 / 4
=	N/A

Evaxion Biotech AS Days Payable Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Evaxion Biotech AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970

Website

https://www.evaxion-biotech.com

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.